OraSure Wins $109M Contract To Increase COVID-19 Test Manufacturing Capacity

• OraSure Technologies Inc (NASDAQ: OSUR) has secured a 9 million contract from the U.S. Department of Defense to build additional manufacturing capacity in the U.S. for InteliSwab COVID-19 rapid tests.

• Related: OraSure Secures .6M BARDA Funding For InteliSwab COVID-19 Test 510(k) Clearance and CLIA Waiver.

• The federal funding will expand OraSure's production capacity by 100 million tests annually by March 2024.

• An existing OraSure location in Bethlehem, Pennsylvania, will be retrofitted to accommodate increased manufacturing, and an additional new facility will be added in another U.S. location.

• In addition to this contract, OraSure also has internally funded expansion plans to achieve 120 million tests annually by Q2 of 2022.

• Related: FDA Establishes Additional Conditions Of Emergency Use Nod For COVID-19 Tests For Viral Mutations.

• Price Action: OSUR stock is up 0.37% at $10.74 on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• FDA Establishes Additional Conditions Of Emergency Use Nod For COVID-19 Tests For Viral Mutations

• OraSure Secures .6M BARDA Funding For InteliSwab COVID-19 Test 510(k) Clearance and CLIA Waiver

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.